NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer TA1041 19 February 2025 19 February 2025 Selpercatinib for previously treated RET ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

NICE guidance published today recommends leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Mental wellbeing is about life satisfaction, optimism, self-esteem, feeling in control, having a purpose and a sense of belonging and support. Older people, including those living in care homes, often ...

NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.